secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuwellis, Inc. (NUWE)
CIK:        0001506492
Form:       8-K
Filed at:   2024-05-07T23:59:59+00:00
Accession:  0001140361-24-024646
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuwellis Q1 revenue up 2% to $1.9M; net loss narrows to $3.8M
-------------------------------------------------------------

- Revenue $1.9M, +2% YoY; consumables sales +11% to 82% of total revenue.
- Gross margin 64.1% vs 58.4%; operating loss improved to $4.7M from $5.8M prior year.
- Net loss $3.8M ($0.60 loss per share) vs $6.5M ($5.76 loss per share) YoY.
- Cash $1.4M, no debt; closed $2.7M underwritten public offering on April 30, 2024.
- Plans approx. 50% expense reduction for rest of 2024; launched REVERSE-HF clinical study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1506492/000114036124024646/0001140361-24-024646-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1506492/000114036124024646/ef20028479_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-24-024646

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer